Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Matthew Caufield
HC
Matthew Caufield
H.C. Wainwright
Wall Street Analyst
★☆☆☆☆
#2392
on 13Foresight · ranked by our own returns
20%
Success Rate
-11.8%
Average Return
4 of 20 calls profitable · -15.3% vs benchmark
📈 Across the calls we could measure, roughly 20% of Matthew Caufield's ratings turned a profit when each position was held for 1 year — averaging -11.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

124 Buy 12 Hold 0 Sell
Matthew's Stock Coverage 21 ratings · 2026-06-20
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
IRD
Opus Genetics
 Jun 17, 2026 BUY Strong Buy
+154.5% avg upside
23 analysts
$8.00
96.63% Upside
 ·
PHAT
Phathom Pharmaceuticals
 Jun 17, 2026 BUY Strong Buy
+163.8% avg upside
14 analysts
$26.00
139.05% Upside
 -1.1%
IMUX
Immunic
 Jun 08, 2026 BUY Strong Buy
+166.0% avg upside
21 analysts
$22.00
55.01% Upside
 +14.9%
ZBIO
Zenas BioPharma, Inc.
 Jun 08, 2026 BUY Strong Buy
+102.2% avg upside
11 analysts
$44.00
122.52% Upside
 +5.5%
UPB
Upstream Bio, Inc.
 Jun 03, 2026 BUY Strong Buy
+514.9% avg upside
9 analysts
$36.00
475.94% Upside
 -15.5%
MLYS
Mineralys Therapeutics, Inc.
 Jun 01, 2026 BUY Strong Buy
+82.7% avg upside
12 analysts
$56.00
127.28% Upside
 -19.2%
SRZN
Surrozen
 May 26, 2026 BUY Buy
+49.6% avg upside
7 analysts
$44.00
89.20% Upside
 -8.1%
TARS
Tarsus Pharmaceuticals
 May 26, 2026 BUY Strong Buy
+20.6% avg upside
16 analysts
$88.00
39.33% Upside
 ·
LENZ
LENZ Therapeutics
 May 12, 2026 BUY Buy
+284.0% avg upside
17 analysts
$38.00
517.89% Upside
 -13.7%
KOD
Kodiak Sciences
 May 11, 2026 BUY Buy
+37.3% avg upside
11 analysts
$58.00
60.58% Upside
 -10.4%
ALDX
Aldeyra Therapeutics
 May 11, 2026 HOLD Strong Buy
+713.6% avg upside
21 analysts
$2.00
2.11% Upside
 -4.5%
FDMT
4D Molecular Therapeutics
 May 11, 2026 BUY Strong Buy
+265.2% avg upside
15 analysts
$36.00
272.69% Upside
 -15.2%
AKBA
Akebia Therapeutics
 May 08, 2026 BUY Strong Buy
+822.0% avg upside
16 analysts
$6.00
460.83% Upside
 -19.3%
DMAC
Diamedica Therapeutics
 May 08, 2026 BUY Strong Buy
+153.0% avg upside
12 analysts
$12.00
105.09% Upside
 -6.5%
ARDX
Ardelyx
 May 01, 2026 BUY Strong Buy
+124.0% avg upside
21 analysts
$18.00
197.58% Upside
 -19.5%
FBLG
FibroBiologics, Inc.
 Apr 16, 2026 BUY Buy
+1198.3% avg upside
4 analysts
$8.00
938.66% Upside
 -27.3%
LYRA
Lyra Therapeutics
 Sep 17, 2025 HOLD Hold
+3282.4% avg upside
7 analysts
$16.00
2253.04% Upside
 -88.3%
OPTEY
Opthea Limited Sponsored ADR
 Aug 22, 2025 HOLD Hold
+37213.4% avg upside
7 analysts
 — ·
HYPD
Hyperion DeFi
 May 27, 2025 HOLD Strong Buy
+143.0% avg upside
8 analysts
 — ·
RGNX
RegenXBio
 Oct 29, 2024 BUY Strong Buy
+381.4% avg upside
22 analysts
$39.00
400.10% Upside
 +41.7%
IRON
Disc Medicine
 Oct 21, 2022 HOLD Strong Buy
+20.2% avg upside
21 analysts
 — -20.7%
🔒 16 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Matthew Caufield — Frequently Asked Questions
How accurate are Matthew Caufield's stock ratings?
Based on the calls 13Foresight could measure, about 20% of Matthew's ratings were profitable over a one-year hold, with an average return of -11.8% per rating, or -15.3% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Matthew ranked on 13Foresight?
Matthew Caufield is currently ranked #2392 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Matthew cover?
Matthew most recently has ratings on IRD, PHAT, IMUX, ZBIO, UPB, MLYS, SRZN, TARS, LENZ, KOD, ALDX, FDMT and 9 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.